Comparing two treatments for a type of esophageal disease.
Official title: Comparative study of dupilumab and fluticasone in management of fibrostenotic Eosinophilic Esophagitis; a pilot and feasibility clinical trial.
Funded at University of Colorado Denver · NIH-11103161 · Data updated 2026-11-12
This study is looking at how well two different treatments work for people with fibrostenotic Eosinophilic Esophagitis, a condition that makes swallowing tough, by comparing a medication called dupilumab with a steroid called fluticasone to see which one helps more.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | June 15, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $252,000 |
| NIH project number | 5R01DK135692-02 |
| Project ID | NIH-11103161 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with fibrostenotic Eosinophilic Esophagitis, both children and adults, who are experiencing significant swallowing difficulties.
✕Less likely to help
Patients who do not have fibrostenotic Eosinophilic Esophagitis or those with other unrelated esophageal conditions may not benefit from this research.
What this research studies
This research investigates the effectiveness of two different treatments for fibrostenotic Eosinophilic Esophagitis (FS-EoE), a condition that causes difficulty swallowing due to inflammation and narrowing of the esophagus. The trial will compare dupilumab, a biologic medication, with fluticasone, a topical corticosteroid, to determine which is more effective in improving symptoms and esophageal function. Patients will be monitored using a novel measurement technique called EndoFLIP, which assesses changes in esophageal narrowing. The goal is to provide valuable data that can guide future treatment options for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with fibrostenotic Eosinophilic Esophagitis, improving their quality of life.
How similar studies have gone: Previous research has shown promising results with biologic treatments for Eosinophilic Esophagitis, indicating that this comparative approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Menard-Katcher, Calies D — University of Colorado Denver
- Study coordinator: Menard-Katcher, Calies D
Related research
Other NIH-funded projects on the same topics.
-
Esophageal antigen test-guided diet for eosinophilic esophagitis
A small, patient-friendly diet approach using a new esophageal antibody test aims to help people with eosinophilic esophagitis identify foods to avoid without repeated invasive procedures.
-
Allergic eosinophilic esophagitis drives dysregulated innate immunity in esophageal fibroblasts
This project studies why eosinophilic esophagitis, a chronic food allergy-related condition, causes lasting changes in the esophagus and how these changes could be treated to prevent scarring and complications.
-
How environmental signals and a receptor may protect or worsen eosinophilic esophagitis
A new NIH grant is exploring how the aryl hydrocarbon receptor (AHR) in the esophagus affects eosinophilic esophagitis (EoE) and how environmental factors might influence this condition.
-
Toward personalized care for pediatric eosinophilic esophagitis using multimodal biomarkers
A pediatric-focused study will combine biochemical, structural, and molecular signals from the esophagus to better tailor treatment for kids with eosinophilic esophagitis.
-
Role of protective proteins in the esophagus to treat eosinophilic esophagitis
A research project aims to understand how certain proteins protect or restore the esophageal lining in children with eosinophilic esophagitis and how this could lead to better long-lasting therapies.
-
Role of 1q21 Genetic Variants in Eosinophilic Esophagitis
This project looks at how genetic differences may make some people with allergies more likely to develop eosinophilic esophagitis (EoE).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.